Is it acceptable to treat patients with limited, asymptomatic brain metastases and EGFR-mutant NSCLC with upfront TKI?  

Though some clinicians have been exploring the idea of targeted therapy for EGFR mutant brain metastases, this has been done in the absence of strong evidence. Reasons for pushing this idea are that sometimes the lesions seem to respond, and this has been seen in some single arm studies and anecdot...

I would treat patients with limited, asymptomatic brain metastases with SRS followed by EGFR-TKI based upon the studies (particularly the recently published Journal of Clinical Oncology study) cited by @James B. Yu above.In full disclosure, I am obviously the first author on both of the manuscr...

I think the answers to this question above make some great points. However, old data on this topic are now a bit outdated with the recent results of the FLAURA trial which moved the third-generation TKI osimertinib to first-line therapy for EGFR-mutants.Most of the first and second-line EGFR agents ...

I often hold off on RT if lesions small and asymptomatic. But I never stop close surveillance. 

I would likely proceed with SRS upfront for limited small metastasis and asymptomatic and consider holding off if patient is comfortable with close surveillance.

In my opinion, patients with asymptomatic brain mets from EGFR-mutated NSCLC can initially be treated with erlotinib. I have had a few such cases, and initially the brain mets respond to erlotinib. However, they appear to universally progress in the brain necessitating radiotherapy or SRS. Studies i...

I would treat with SRS now to prevent problems in future. Besides, I think patients with known brain mets will really worry if not treated.

I would treat excelt if patient wishes to be on close surveillance with repeat MRI. Most of my patients prefer treatment than getting freq MRI studies.